SNY : NYSE : Health Care
$49.03 | %
Today's Range: 0.0 - 0.0
Avg. Daily Volume: 1718100.0
05/25/17 - 4:02 PM ET

Financial Analysis


SANOFI's gross profit margin for the first quarter of its fiscal year 2017 is essentially unchanged when compared to the same period a year ago. The company has grown its sales and net income during the past quarter when compared with the same quarter a year ago, and although its growth in net income has outpaced the industry average, its revenue growth has not.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY17 Q1 FY16
Net Sales ($mil)9518.019029.99
EBITDA ($mil)0.00.0
EBIT ($mil)1949.181811.01
Net Income ($mil)6098.931238.09


Balance Sheet Q1 FY17 Q1 FY16
Cash & Equiv. ($mil)0.00.0
Total Assets ($mil)0.00.0
Total Debt ($mil)0.00.0
Equity ($mil)0.00.0


Profitability Q1 FY17 Q1 FY16
Gross Profit Margin63.0463.53
EBITDA Margin0.00.0
Operating Margin20.4820.06
Sales Turnover0.00.0
Return on Assets0.00.0
Return on Equity0.00.0
Debt Q1 FY17 Q1 FY16
Current Ratio0.00.0
Debt/Capital0.00.0
Interest Expense118.75146.93
Interest Coverage16.4112.33


Share Data Q1 FY17 Q1 FY16
Shares outstanding (mil)2543.882603.48
Div / share0.00.0
EPS0.530.44
Book value / share0.00.0
Institutional Own % n/a n/a
Avg Daily Volume1704429.01868089.0

Valuation


BUY. The current P/E ratio indicates a significant discount compared to an average of 87.33 for the Pharmaceuticals industry and a value on par with the S&P 500 average of 25.02. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, SANOFI proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
SNY 26.01 Peers 87.33   SNY NA Peers 19.75

Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.

SNY is trading at a significant discount to its peers.

 

Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures.

Ratio not available.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
SNY 14.85 Peers 15.90   SNY 0.36 Peers 0.73

Average. An average price-to-projected earnings ratio can signify an industry neutral stock price and average future growth expectations.

SNY is trading at a valuation on par with its peers.

 

Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

SNY trades at a significant discount to its peers.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
SNY NA Peers 13.78   SNY 2.16 Peers -3.58

Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

Ratio not available.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

SNY is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
SNY 3.37 Peers 14.05   SNY -2.49 Peers 4.04

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

SNY is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

SNY significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades